Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy

References

• Tocci G, Sciarretta S, Facciolo C, Volpe M. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Rev. Cardiovasc. Ther.5(4), 767–776 (2007).
   PubMedGoogle Scholar
• Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med.165(12), 1410–1419 (2005).
   PubMed Web of Science ®Google Scholar
• Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet362(9395), 1527–1535 (2003).
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ336(7653), 1121–1123 (2008).
   PubMed Web of Science ®Google Scholar
• Williams B. The year in hypertension. J. Am. Coll. Cardiol.55(1), 65–73 (2009).
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet373(9667), 929–940 (2009).
   PubMed Web of Science ®Google Scholar
• Whyte JL, Lapuerta P, L’Italien GJ, Franklin SS. The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988–1994. J. Clin. Hypertens. (Greenwich)3(4), 211–216 (2001).
   PubMedGoogle Scholar
• Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension43(1), 10–17 (2004).
   PubMed Web of Science ®Google Scholar
• Bramlage P, Bohm M, Volpe M et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J. Clin. Hypertens. (Greenwich)12(9), 666–677 (2010).
   PubMed Web of Science ®Google Scholar
• Tocci G, Giovannelli F, Sciarretta S, Ferrucci A, Zito GB, Volpe M. Management of hypertension and stroke prevention: results of the Italian cardiologist survey. Int. J. Clin. Pract.63(2), 207–216 (2009).
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT). Expert Rev. Cardiovasc. Ther.1(3), 335–343 (2003).
   PubMedGoogle Scholar
• Tocci G, Palano F, Pagannone E, Chin D, Ferrucci A, Volpe M. Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine. Expert Rev. Cardiovasc. Ther.7(2), 115–123 (2009).
   PubMedGoogle Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens.25(9), 1751–1762 (2007).
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens.27(11), 2121–2158.(2009).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42(6), 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ328(7440), 634–640 (2004).
   PubMed Web of Science ®Google Scholar
• Chobanian AV. Shattuck Lecture. The hypertension paradox – more uncontrolled disease despite improved therapy. N. Engl. J. Med.361(9), 878–887 (2009).
   PubMed Web of Science ®Google Scholar
• Angeli F, Verdecchia P, Reboldi GP et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am. J. Hypertens.17(9), 817–822 (2004).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J. Hypertens.21(6), 1055–1076 (2003).
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J. Hypertens.20(8), 1461–1464 (2002).
   PubMed Web of Science ®Google Scholar
• Leonetti G, Cuspidi C, Facchini M. [Antihypertensive therapy in the elderly: results of large trials]. Ital. Heart J. Suppl.2(11), 1161–1169 (2001).
   PubMedGoogle Scholar
• ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288(23), 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359(23), 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Volpe M, Tocci G, Pagannone E. Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin–angiotensin–aldosterone system. J. Am. Soc. Nephrol.17(4 Suppl. 2), S36–S43 (2006).
   Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet359(9311), 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet366(9489), 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359(23), 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ326(7404), 1427 (2003).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension55(2), 399–407 (2010).
   PubMed Web of Science ®Google Scholar
• Messerli FH, Michalewicz L. Cardiac effects of combination therapy. Am. J. Hypertens.10(7 Pt 2), 146S–152S (1997).
   Web of Science ®Google Scholar
• Messerli FH, Grossman E, Michalewicz L. Combination therapy and target organ protection in hypertension and diabetes mellitus. Am. J. Hypertens.10(9 Pt 2), 198S–201S (1997).
   Web of Science ®Google Scholar
• Messerli FH. Combination therapy in hypertension. J. Hum. Hypertens.6(Suppl. 2), S19–S21 (1992).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Shahane A, Parkar S, Messerli FH. Compliance and fixed-dose combination therapy. Curr. Hypertens. Rep.9(3), 184–189 (2007).
   PubMed Web of Science ®Google Scholar
• Ruschitzka FT, Noll G, Luscher TF. Combination of ACE inhibitors and calcium antagonists: a logical approach. J. Cardiovasc. Pharmacol.31(Suppl. 2), S5–S16 (1998).
   PubMedGoogle Scholar
• Volpe M, Tocci G. Therapeutic implications of recent megatrials in hypertension: in favor of new drugs. J. Nephrol.20(Suppl. 12), S12–S18 (2007).
   Google Scholar
• Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with β blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol.100(8), 1254–1262 (2007).
   PubMed Web of Science ®Google Scholar
• Warner GT, Jarvis B. Olmesartan medoxomil. Drugs62(9), 1345–1353; discussion 1354–1346 (2002).
   PubMed Web of Science ®Google Scholar
• Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs68(9), 1239–1272 (2008).
   PubMed Web of Science ®Google Scholar
• Unger T, McInnes GT, Neutel JM, Bohm M. The role of olmesartan medoxomil in the management of hypertension. Drugs64(24), 2731–2739 (2004).
   PubMed Web of Science ®Google Scholar
• Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J. Hypertens.25(7), 1327–1336 (2007).
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Chrysant GS. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin. Pharmacother.5(3), 657–667 (2004).
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension. Expert Rev. Cardiovasc. Ther.7(8), 887–895 (2009).
   PubMedGoogle Scholar
• Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am. J. Hypertens.17(3), 252–259 (2004).
   PubMed Web of Science ®Google Scholar
• Barrios V, Boccanelli A, Ewald S et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin. Drug Investig.27(8), 545–558 (2007).
   PubMed Web of Science ®Google Scholar
• Oparil S, Chrysant SG, Kereiakes D et al. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J. Clin. Hypertens. (Greenwich)10(12), 911–921 (2008).
   PubMed Web of Science ®Google Scholar
• Izzo JL Jr, Neutel JM, Silfani T, Dubiel R, Walker F. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J. Clin. Hypertens. (Greenwich)9(1), 36–44 (2007).
   PubMedGoogle Scholar
• Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin. Ther.30(4), 587–604 (2008).
   PubMed Web of Science ®Google Scholar
• Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate-to-severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin. Drug Investig.29(1), 11–25 (2009).
   PubMed Web of Science ®Google Scholar
• Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin. Drug Investig.29(6), 381–391 (2009).
   PubMed Web of Science ®Google Scholar
• Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin. Ther.32(7), 1252–1269 (2010).
   PubMed Web of Science ®Google Scholar
• Izzo JL Jr, Neutel JM, Silfani T, Dubiel R, Walker F. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J. Clin. Hypertens. (Greenwich)9(1), 36–44 (2007).
   PubMedGoogle Scholar
• Kereiakes DJ, Neutel J, Stoakes KA et al. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older. J. Clin. Hypertens. (Greenwich)11(8), 411–421 (2009).
   PubMed Web of Science ®Google Scholar
• Punzi H, Neutel JM, Kereiakes DJ et al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther. Adv. Cardiovasc. Dis.4(4), 209–221 (2010).
   PubMedGoogle Scholar
• Neutel JM, Smith DH, Weber MA, Wang AC, Masonson HN. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control.[erratum appears in J. Clin. Hypertens. (Greenwich) 2004 Jun; 6(6): 346]. J. Clin. Hypertens. (Greenwich)6(4), 168–174 (2004).
   Google Scholar
• Sellin L, Stegbauer J, Laeis P, Rump LC. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J. Hypertens.23(11), 2083–2092 (2005).
   PubMed Web of Science ®Google Scholar
• Neutel JM, Kereiakes DJ, Waverczak WF, Stoakes KA, Xu J, Shojaee A. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and Type 2 diabetes. Curr. Med. Res. Opin.26(3), 721–728 (2010).
   PubMed Web of Science ®Google Scholar